Abcam Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Abcam stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABCM, but not buy additional shares or sell existing shares.
View analyst ratings for Abcam or view top-rated stocks.

Wall Street analysts have given Abcam a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abcam wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Abcam saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 63,600 shares, an increase of 63.1% from the February 28th total of 39,000 shares. Based on an average trading volume of 205,800 shares, the short-interest ratio is currently 0.3 days.
View Abcam's Short Interest.

7 analysts have issued twelve-month price targets for Abcam's shares. Their forecasts range from $20.00 to $25.00. On average, they expect Abcam's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 10.6% from the stock's current price.
View analysts' price targets for Abcam or view top-rated stocks among Wall Street analysts.

Some companies that are related to Abcam include AbCellera Biologics (ABCL), Sana Biotechnology (SANA), Cronos Group (CRON), Genus (GNS), Abcam (ABC), BTG (BTG), Seer (SEER), MorphoSys (MOR), Nuvation Bio (NUVB), ImmunityBio (IBRX), BioAtla (BCAB), Immunocore (IMCR), Cullinan Oncology (CGEM), Cricut (EWTX) and Kinnate Biopharma (KNTE).
View all of ABCM's competitors.

(ABCM) raised $149 million in an initial public offering (IPO) on Thursday, October 22nd 2020. The company issued 9,000,000 shares at a price of $16.52 per share. Morgan Stanley, BofA Securities, SVB Leerink, Lazard and William Blair served as the underwriters for the IPO.

Abcam trades on the NASDAQ under the ticker symbol "ABCM."

Abcam's lock-up period expires on Tuesday, April 20th. Abcam had issued 8,945,218 shares in its IPO on October 22nd. The total size of the offering was $156,541,315 based on an initial share price of $17.50. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Shares of ABCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABCM stock can currently be purchased for approximately $19.89.

Abcam has a market capitalization of $4.51 billion.

Abcam employs 1,492 workers across the globe.

The official website for Abcam is www.abcam.com.

The company can be reached via phone at 44 1223 696 000.